Fatty liver disease (MASLD/MASH) trials in Belgium

In Belgium 16 Also abroad 367

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Anderlecht, Edegem, Genk, Gent, Leuven, Liège, Namur, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Anderlecht, Edegem, Genk, Liège
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Anderlecht, Edegem, Gent
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Anderlecht, Brussels, Edegem, Genk, Gent, Jette
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Anderlecht, Edegem, Genk, Gent, Jette, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Not yet taking people in Belgium
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Belgium
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Brussels, Edegem, Ghent, Kortrijk, Ostend, Roeselare, Sint-Niklaas
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Where
Brussels, Louvain-la-Neuve
Age
18 years to 70 years
People
60
Run by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06506513
Phase 1Taking people
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Where
Edegem
Age
18 years to 65 years
People
124
Run by
Boehringer Ingelheim
See details and how to joinNCT06575400
No phaseTaking people
Prevalence of NAFLD in T1DM Patients
Where
Genk
Age
18 years and over
People
138
Run by
Ziekenhuis Oost-Limburg
See details and how to joinNCT06445361
No phaseTaking people
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Where
Brussels
Age
18 years and over
People
150
Run by
Centre Hospitalier Universitaire Saint Pierre
See details and how to joinNCT06814600
No phaseTaking people
Global Research Initiative for Patients Screening on MASH
Where
Antwerp, Brussels
Age
18 years to 75 years
People
10,000 worldwide
Run by
Julius Clinical
See details and how to joinNCT05651724
No phaseTaking people
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Where
De Haan, Ghent
Age
8 years to 18 years
People
850
Run by
University Hospital, Ghent
See details and how to joinNCT05309863
No phaseTaking people
The European NAFLD Registry
Where
Antwerp
Age
18 years to 100 years
People
10,000 worldwide
Run by
Newcastle University
See details and how to joinNCT04442334